Synthesis, in vitro enzyme activity and molecular docking studies of new benzylamine-sulfonamide derivatives as selective MAO-B inhibitors

References

• Xu R, Xiao G, Li Y, et al. Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease. Bioorg Med Chem 2018;26:1885–9.
   PubMed Web of Science ®Google Scholar
• Kaya B, Sağlık BN, Levent S, et al. Synthesis of some novel 2-substituted benzothiazole derivatives containing benzylamine moiety as monoamine oxidase inhibitory agents. J Enzyme Inhib Med Chem 2016;31:1654–61.
   PubMed Web of Science ®Google Scholar
• Tripathi RKP, Ayyannan SR. Design, synthesis, and evaluation of 2-amino-6-nitrobenzothiazole-derived hydrazones as MAO inhibitors: role of the methylene spacer group. ChemMEdChem 2016;11:1551–67.
   PubMed Web of Science ®Google Scholar
• Zenn RK, Abad E, Kastner J. Influence of the environment on the oxidative deamination of p-substituted benzylamines in monoamine oxidase. J Phys Chem B 2015;119:3678–86.
   PubMed Web of Science ®Google Scholar
• Mathew B, Parambi DG, Mathew GE, et al. Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. Arch Pharm 2019;352:1900177.
   PubMed Web of Science ®Google Scholar
• Jiang T, Sun Q, Chen S. Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease. Prog Neurobiol 2016;147:1–19.
   PubMed Web of Science ®Google Scholar
• Mathew B, Suresh J, Mathew GE, et al. Plant secondary metabolites- potent inhibitors of monoamine oxidase isoforms. Cent Nerv Syst Agents Med Chem 2014;14:28–33.
   PubMedGoogle Scholar
• Fonseca A, Reis J, Silva T, et al. Coumarin versus chromone monoamine oxidase B inhibitors: quo vadis. J Med Chem 2017;60:7206–12.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Dahiya N. Management of Parkinson's disease: current and future pharmacotherapy. Eur. J. Pharmacol 2015;750:74–81.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Safinamide: first global approval. Drugs 2015;75:705–11.
   PubMed Web of Science ®Google Scholar
• Legoabe L, Kruger J, Petzer A, et al. Monoamine oxidase inhibition by selected anilide derivatives. Eur J Med Chem 2011;46:5162–74.
   PubMed Web of Science ®Google Scholar
• Saddique FA, Zaib S, Jalil S, et al. Synthesis, monoamine oxidase inhibition activity and molecular docking studies of novel 4-hydroxy-N'-[benzylidene or 1-phenylethylidene]-2-H/methyl/benzyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides. Eur J Med Chem 2018;143:1373–86.
   PubMed Web of Science ®Google Scholar
• Lu X, Rodríguez M, Gu W, et al. Inactivation of mitochondrial monoamine oxidase B by methylthio-substituted benzylamines. Bioorg Med Chem 2003;11:4423–30.
   PubMed Web of Science ®Google Scholar
• Upadhyay AK, Edmondson DR. Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B. Biochemistry 2009;48:3928–35.
   PubMed Web of Science ®Google Scholar
• Tripathi RK, Goshain O, Ayyannan SR. Design, synthesis, in vitro MAO-B inhibitory evaluation, and computational studies of some 6-nitrobenzothiazole-derived semicarbazones. ChemMEdChem 2013;8:462–74.
   PubMed Web of Science ®Google Scholar
• Tavari M, Malan SF, Joubert J. Design, synthesis, biological evaluation and docking studies of sulfonyl isatin derivatives as monoamine oxidase and caspase-3 inhibitors. Med Chem Commun 2016;7:1628–39.
   Web of Science ®Google Scholar
• Ilgın S, Osmaniye D, Levent S, et al. Design and synthesis of new benzothiazole compounds as selective hMAO-B inhibitors. Molecules 2017;22:2187.
   Web of Science ®Google Scholar
• Nam MH, Park M, Park H, et al. Indole-substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson's Disease. ACS Chem Neurosci 2017;8:1519–29.
   PubMed Web of Science ®Google Scholar
• Turan-Zitouni G, Hussein W, Sağlık BN, et al. Design, synthesis and biological evaluation of novel N-pyridyl-hydrazone derivatives as potential monoamine oxidase (MAO) inhibitors. Molecules 2018;23:113.
   Google Scholar
• Can ÖD, Osmaniye D, Demir Özkay Ü, et al. MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains. Eur J Med Chem 2017;131:92–106.
   PubMed Web of Science ®Google Scholar
• Can NÖ, Osmaniye D, Levent S, et al. Synthesis of new hydrazone derivatives for MAO enzymes inhibitory activity. Molecules 2017;22:1381.
   Web of Science ®Google Scholar
• Can NÖ, Osmaniye D, Levent S, et al. Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors. Eur J Med Chem 2018;144:68–81.
   PubMed Web of Science ®Google Scholar
• Sağlık BN, Ilgın S, Özkay YS, et al. "Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes. Eur J Med Chem 2016;124:1026–40.
   PubMed Web of Science ®Google Scholar
• Demir Özkay Ü, Can ÖD, Sağlık BN, et al. Design, synthesis, and AChE inhibitory activity of new benzothiazole-piperazines. Bioorg Med Chem Lett 2016;26:5387–94.
   PubMed Web of Science ®Google Scholar
• Patel S, Ghewala N, Suthar A, et al. In-vitro cytotoxicity activity of Solanum nigrum extract against Hela cell line and Vero cell line. Int J Pharm Sci 2009;1:38–46.
   Google Scholar
• QikProp, version 4.8, Schrödinger, LLC, New York, NY; 2016.
   Google Scholar
• Claudia B, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50:5848–52.
   PubMed Web of Science ®Google Scholar
• Maestro, version 10.6, Schrödinger, LLC, New York, NY; 2016.
   Google Scholar
• Schrödinger, LLC, New York, NY; 2016.
   Google Scholar
• LigPrep, version 3.8, Schrödinger, LLC, New York, NY; 2016.
   Google Scholar
• Glide, version 7.1, Schrödinger, LLC, New York, NY; 2016.
   Google Scholar
• Toprakçı M, Yelekçi K. Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett 2005;15:4438–46.
   PubMed Web of Science ®Google Scholar
• Gökhan-Kelekçi N, Şimşek ÖÖ, Ercan A, et al. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. Bioorg Med Chem 2009;17:6761–72.
   PubMedGoogle Scholar
• Evranos-Aksöz B, Yabanoğlu-Çiftçi S, Uçar G, et al. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory activities and docking studies. Bioorg Med Chem Lett 2014;24:3278–84.
   PubMed Web of Science ®Google Scholar
• De Waterbeemd HV, Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat Rev Drug Discov 2003;2:192–204.
   PubMed Web of Science ®Google Scholar
• Henchoz Y, Bard B, Guillarme D, et al. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution. Anal Bioanal Chem 2009;394:707–29.
   PubMed Web of Science ®Google Scholar
• Kerns EH. High throughput physicochemical profiling for drug discovery. J Pharm Sci 2001;90:1838–58.
   PubMed Web of Science ®Google Scholar
• Kerns EH, Di L. Physicochemical profiling: overview of the screens. Drug Discov Today Technol 2004;1:343–8.
   PubMedGoogle Scholar
• Jorgensen WL, Duffy EM. Prediction of drug solubility from structure. Adv Drug Deliv Rev 2002;54:355–66.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Dunitz JD, Taylor R. Organic fluorine hardly ever accepts hydrogen bonds. Chem-A Eur J Med Chem 1997;3:89–98.
   Web of Science ®Google Scholar